Published on 1 December 2022
Description:
New PharmaTimes seizes the zeitgeist by focusing on the era-defining importance of including the LGBTQ+ community and upholding diversity in all clinical trials. We also look forward to the year ahead by focusing on intelligent resourcing, accelerating innovation, striving for health equality and maximising patient data across the brave new pharma world.
Categories:
PharmaTimesPreview:
27 articles from this collection:
Cover
2 - PharmaTimes Marketer of the Year
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: Clinical Trials
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-11 - COVER STORY: Minority Report
12 - CLINICAL TRIALS: Trial Blazers
13 - SUSTAINABILITY: Reality Checked
14-15 - RESEARCH: STEM sell
16-17 - EQUITY: Chat Room
18-20 - OPTIMISATION: The force awakens?
21 - SAMEDAN
22-23 - INNOVATION: We are the robots
24-25 - FUTURE: Data day
26 - MARKET: You’ve been frame worked
27 - AI: History channel
28 -29 - DIABETES: Killer at large
30-31 - R&D: Time is of the essence
32-33 - VISION: In our sights
34-35 - Your moves
36-37 - NHS: Long and winding road
38 - INTCROY
39 - PHARMAROLE
38 - SAMEDAN
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.